Addex Therapeutics

#allostericmodulators #financialresults addextherapeutics.com/en/investors/p…

On Thursday, December 4, we will release our Third Quarter 2025 Financial Results. Join our CEO, Tim Dyer, and Mikhail Kalinichev, Head of Translational Science, as they discuss the results and provide a corporate update during a conference call and webcast.

followed by a Q&A session. If you would like to join the call, links are available in our press release below. addextherapeutics.com/en/investors/p…

Today we released our first half 2025 financial results. Our CEO, Tim Dyer and Head of Translational Science, Mikhail Kalinichev, will discuss the financial results in a conference call tomorrow, October 1, 2025, at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) in a presentation

for CNS disorders and follows our spin-out and 20% holding in @neurosterix . #allostericmodulators #precisionpsychiatry #biotechinvestment #CNSdrugdevelopment

We are excited to lead a CHF2 million investment in @stalicla_sa , a fellow clinical-stage Swiss biotech focused on precision medicine for neurodevelopmental and neuropsychiatric disorders. This strategic investment supports our commitment to advancing innovative treatments

will host a conference call at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) to discuss the results and provide a corporate update. To join the call, see details in the link to the press release below. #financialresults #allostericmodulation #drugdevelopment

Today, we announced our Q1 2025 Financial Results, showing progress on both product development and delivering on our business strategy. Our CEO, Tim Dyer, and Mikhail Kalinichev, Head of Translational Science,

Details for joining the call are provided in the link below. #financialresults #allostericmodulation #drugdevelopment addextherapeutics.com/en/investors/p…

Tomorrow we will issue our Q1 2025 Financial Results. Our CEO, Tim Dyer, and Mikhail Kalinichev, Head of Translational Science, will host a conference call and webcast at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) to discuss the results and provide a corporate update.

If you're attending the conference and would like to know more, we welcome the opportunity to connect and discuss. Please contact us on IR@addexpharma.com. #chroniccough #allostericmodulator #GABABPAM addextherapeutics.com/en/investors/p…

On Saturday, Mikhail Kalinichev, our Head of Translational Science will present the progress we’ve made in our GABAB PAM cough program at the 10th American Cough Conference.

At Addex, we continue to advance our own GABAB PAM chronic cough program through preclinical development. Both programs emerged from our research collaboration with Indivior. addextherapeutics.com/en/investors/p… #allostericmodulators #chroniccough #GABAB #drugdiscovery

Congratulations to partner Indivior PLC, which has successfully advanced its GABAB positive allostericmodulator (PAM) program for substance use disorders through IND enabling studies.

#allostericmodulators #strokeawareness #brainrecovery

so survivors often suffer with severe brain injury and resulting disabilities. We believe that mGlu5 NAMs could improve recovery of function in these patients. Dipraglurant, our phase 2 ready mGlu5 NAM, is a promising candidate to help patients with brain injury recover better.

May is stroke awareness month. As the fifth leading cause of death in the U.S., much still needs to be done to alleviate the impact of this devastating condition. Nearly 2 million brain cells die each minute a stroke remains untreated,